IRTCiRhythm Holdings, Inc.
Price
-39%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, nothing alarming, demanding price, growing in the filings, the market undecided.
We are a leading digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Our principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that we believe allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology.
In the company’s own words · 10-K filed Feb 19, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
iRhythm Holdings, Inc. (IRTC) reported revenue of $224M in Q2 2026 (quarter ended Jun 30, 2026), up 20% from the same quarter a year earlier. That came with a gross margin of 73% and net loss of $381K. For the full year FY2025, revenue was $747M (+26% year on year) and net income −$45M. Its largest product in Q2 2026 was Commercial Payors at $114M, 51% of the disclosed total, well ahead of Centers For Medicare Medicaid Services at 26%. The next results filing is expected around Oct 29, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 13, 2026On August 11, 2026, Brian Yoor notified iRhythm Holdings, Inc. (the “Company”) of his decision to resign from his position as a member of the Board of Directors of the Company (the “Board”) and as a member and chair of the Audit Committee of the Board (the “Audit Committee”), effective August 12, 2026.Director or officer change · Form 8-K
- Aug 6, 2026On August 5, 2026, iRhythm Holdings, Inc., a Delaware corporation (“iRhythm” or the “Company”), iRhythm Technologies, Inc., a Delaware corporation and a direct wholly owned subsidiary of iRhythm (“Acquirer”), Project Vessel Merger Sub, Inc., a newly formed Delaware corporation and a direct wholly owned subsidiary of …Material agreement entered · Form 8-K
- Aug 6, 2026As previously disclosed, iRhythm Technologies, Inc. ("iRhythm Technologies"), a wholly owned subsidiary of iRhythm Holdings, Inc. (the “Company”), has been involved in patent litigation with Welch Allyn, Inc. and Bardy Diagnostics, Inc., wholly-owned subsidiaries of Baxter International, Inc. (the foregoing entities …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $224.2MThe company’s own SEC segment disclosure.
- Commercial Payors$113.8M51%
- Centers For Medicare Medicaid Services$58.5M26%
- Healthcare Institutions$37.8M17%
- Non Contracted Third Party Payors$14.1M6%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.